Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6456147 | 0.72 | CYP2C9 (0.41) | CYP2C9EPHX2HSD11B1 | |
| SCHEMBL4412291 | 0.71 | CYP2C9 (0.45) | CYP2C9EPHX2HSD11B1 | |
| SCHEMBL26709231 | 0.69 | CYP2C9 (0.38) | CYP2C9EPHX2HSD11B1 | |
| SCHEMBL10239375 | 0.69 | CYP2C9 (0.38) | CYP2C9EPHX2 | |
| SCHEMBL2190383 | 0.67 | EPHX2 (0.39) | CYP2C9EPHX2HSD11B1 | |
| SCHEMBL6346244 | 0.67 | CYP2C9 (0.36) | CYP2C9EPHX2HSD11B1 | |
| SCHEMBL12193712 | 0.65 | CYP2C9 (0.35) | CYP2C9EPHX2 | |
| SCHEMBL4067305 | 0.65 | CYP2C9 (0.38) | CYP2C9EPHX2 | |
| Adamantane SCHEMBL31336320 | 0.62 | CYP2C9 (0.43) | CYP2C9EPHX2 | |
| SCHEMBL3282039 | 0.61 | CYP2C9 (0.35) | CYP2C9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776510-B2 | Comprising base component which exhibits changed solubility in an alkali developing solution under action of acid and an acid-generator component which generates acid upon irradiation | TOKYO OHKA KOGYO CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20080311522-A1 | Comprising base component which exhibits changed solubility in an alkali developing solution under action of acid and an acid-generator component which generates acid upon irradiation | TOKYO OHKA KOGYO CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311522-A1 | Comprising base component which exhibits changed solubility in an alkali developing solution under action of acid and an acid-generator component which generates acid upon irradiation | GNG2, ACAD9, SCO2 | CYP2C9 144/4885EPHX2 176/4885HSD11B1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.